Match!

Nanotherapeutics in glioma management: Advances and future perspectives

Published on Jun 1, 2020in Journal of Drug Delivery Science and Technology2.606
· DOI :10.1016/J.JDDST.2020.101626
Abstract
Abstract Glioblastoma Multiforme management is one the most challenging task in clinical oncology. The blood brain barrier (BBB) possesses a huge hurdle for the brain in terms of drug delivery. In a healthy brain, it performs important functions such as protecting the brain from harmful toxins by not allowing them to cross the BBB. However, in glioma, the normal composition of the BBB is disrupted which makes it difficult for the entry of drugs to the targeted site. This review provides a brief overview on the various strategies employed to treat glioma. The various strategies employed to treat glioma includes surgery, chemotherapy, radiotherapy, angiogenesis inhibitors, alternating electric field therapy and gamma knife surgery. All the current strategies employed in treating glioma possess its own pros and cons. Though surgery is widely followed, removal of the entire tumor is difficult due to the invasive nature of the cancer cells and there is a high chance of relapse. Chemotherapy also fails since many of the drugs cannot cross the blood brain barrier. Gamma knife surgery is effective since high dose of radiations are used but the treatment is very expensive and is not affordable by all the patients. Hence there is a need to find an alternative strategy to treat glioma which is effective and affordable. Currently the most advanced technology in treating glioma is by introducing nanotherapeutics, which ensures the targeted delivery.
  • References (84)
  • Citations (0)
📖 Papers frequently viewed together
5 Authors (Menghuan Li, ..., Kaiyong Cai)
5 Citations
2017
3 Authors (Ajeet Kaushik, ..., Madhavan Nair)
5 Citations
2017
3 Authors (Gerardo Caruso, ..., Maria Caffo)
78% of Scinapse members use related papers. After signing in, all features are FREE.
References84
Newest
#1Kripi Vohra (Maharshi Dayanand University)H-Index: 1
#2Harish Dureja (Maharshi Dayanand University)H-Index: 13
Last. Rohit Dutt (GD Goenka University)H-Index: 3
view all 4 authors...
1 CitationsSource
#1Tresa McGranahan (UW: University of Washington)H-Index: 3
#2Kate Elizabeth Therkelsen (Stanford University)H-Index: 2
Last. Seema Nagpal (Stanford University)H-Index: 17
view all 4 authors...
At this time, there are no FDA-approved immune therapies for glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a highly immunosuppressive tumor and there are limitations to a safe immune response in the central nervous system. To date, there have been several failures of phase 3 immune therapy clinical trials in GBM. These trials have targeted single components of an antitumor immune response. Learning from these failures, the future of immunotherapy for GBM a...
4 CitationsSource
Over the past century, treatment of malignant tumors of the brain has remained a challenge. Refinements in neurosurgical techniques, discovery of powerful chemotherapeutic agents, advances in radiotherapy, applications of biotechnology, and improvements in methods of targeted delivery have led to some extension of length of survival of glioblastoma patients. Refinements in surgery are mentioned because most of the patients with glioblastoma undergo surgery and many of the other innovative therap...
11 CitationsSource
#1Maria MendesH-Index: 5
#2João J.S. SousaH-Index: 20
Last. Carla VitorinoH-Index: 9
view all 4 authors...
The poor prognosis and rapid recurrence of glioblastoma (GB) are associated to its fast-growing process and invasive nature, which make difficult the complete removal of the cancer infiltrated tissues. Additionally, GB heterogeneity within and between patients demands a patient-focused method of treatment. Thus, the implementation of nanotechnology is an attractive approach considering all anatomic issues of GB, since it will potentially improve brain drug distribution, due to the interaction be...
2 CitationsSource
Source
Viruses have evolved to cause both indolent and explosive disease outbreaks, with millions of people infected with the human immunodeficiency virus and hepatitis viruses and with the current outbreaks of Ebola, yellow fever, and Zika viruses in various parts of the world. As a result of intense study, we have learned how viruses cause disease, which genes are responsible, and how they work. The resultant discoveries have led to the development of improved vaccines1 and the development of strateg...
1 CitationsSource
#1Muhammad Umar Farooq (University of Electronic Science and Technology of China)H-Index: 2
#2Valentyn Novosad (National University of Science and Technology)H-Index: 33
Last. Zhiming Wang (University of Electronic Science and Technology of China)H-Index: 35
view all 9 authors...
Colloidal gold nanoparticles (AuNPs) are of interest as non-toxic carriers for drug delivery owing to their advanced properties, such as extensive surface-to-volume ratio and possibilities for tailoring their charge, hydrophilicity and functionality through surface chemistries. To date, various biocompatible polymers have been used for surface decoration of AuNPs to enhance their stability, payloads capacity and cellular uptake. This study describes a facile one-step method to synthesize stable ...
26 CitationsSource
#1Jung Seok Kim (Sookmyung Women's University)H-Index: 2
#2Dae Hwan Shin (Mokpo National University)H-Index: 7
Last. Jin-Seok Kim (Sookmyung Women's University)H-Index: 19
view all 3 authors...
Abstract Glioblastoma stem cells (GSCs), which are identified as subpopulation of CD133 + /ALDH1 + , are known to show resistance to the most of chemotherapy and radiation therapy, leading to the recurrence of tumor in glioblastoma multiforme (GBM) patients. Also, delivery of temozolomide (TMZ), a mainline treatment of GBM, to the GBM site is hampered by various barriers including the blood-brain barrier (BBB). A dual-targeting immunoliposome encapsulating TMZ (Dual-LP-TMZ) was developed by usin...
12 CitationsSource
Glioblastoma (GBM) is the most common primary intracranial neoplasia, and is characterized by its extremely poor prognosis. Despite maximum surgery, chemotherapy, and radiation, the histological heterogeneity of GBM makes total eradication impossible, due to residual cancer cells invading the parenchyma, which is not otherwise seen in radiographic images. Even with gross total resection, the heterogeneity and the dormant nature of brain tumor initiating cells allow for therapeutic evasion, contr...
30 CitationsSource
#1Russell Maxwell (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 6
#2Christopher Jackson (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 18
Last. Michael Lim (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 35
view all 3 authors...
Immune checkpoint inhibitors have changed the landscape of cancer immunotherapy and are being integrated into the standard of care for a variety of solid and hematologic malignancies. Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and carries a grave prognosis despite advances in surgical resection, chemotherapy, and radiation therapy. Implementing immunotherapy for brain tumors mandates additional considerations due to the unique structural and immunologic milieu ...
25 CitationsSource
Cited By0
Newest